August 24, 2005 NeoPharm received FDA approval for an interim analysis of a Phase III trial of its brain cancer drug, Cell Therapeutics will seek approval of Xyotax as a lung cancer therapy even though it did not meet Phase III primary endpoints, Altana has given a diarrhea medication back to its partner Salix, Caraco won FDA approval for a third dose of an antipsychotic drug, and CV Therapeutics and Solvay Pharma said they won approval of an additional indication for Aceon, their cardiovascular treatment. Biotech slipped lower at the end of the session, with the Centient Biotech 200™ off by 7 points at 3739.60, a loss of .19%.
